Survodutide features a designed peptide backbone containing hydrophobic, polar, and charged residues that modulate solubility and folding. Researchers evaluate its structure-activity behavior and conformational preferences. The sequence supports studies of receptor-ligand determinants. Applications include peptide engineering, structural optimization, and binding analysis.
CAT No: R2481
CAS No:2805997-46-8
Synonyms/Alias:Survodutide;2805997-46-8;GTPL13383;EX-A7878;BI456906;BI 456906;
Survodutide, also known as NN9828, is a synthetic peptide designed as a dual agonist for both glucagon and glucagon-like peptide-1 (GLP-1) receptors. As an innovative molecule within the incretin mimetic class, Survodutide demonstrates a unique mechanism of action by simultaneously targeting metabolic pathways involved in glucose regulation, energy expenditure, and appetite control. Its advanced structure allows for enhanced receptor selectivity and potency, making it a valuable tool in scientific research focused on metabolic functions. Survodutide's stability and bioactivity in preclinical models have attracted interest from academic and pharmaceutical laboratories aiming to elucidate the complex interplay between hormonal signaling and metabolic homeostasis. The compound's dual receptor activity provides a versatile platform for experimental investigation into the multifaceted roles of glucagon and GLP-1 in physiology and disease models.
Metabolic Disease Research: Survodutide serves as a powerful agent for investigating the underlying mechanisms of metabolic disorders such as obesity and type 2 diabetes. By activating both glucagon and GLP-1 receptors, researchers can explore how this dual agonism impacts glucose metabolism, insulin sensitivity, and lipid profiles in various animal models. Experimental protocols may incorporate Survodutide to induce or modulate metabolic pathways, allowing scientists to dissect the contributions of individual signaling cascades and their interactions. These insights are crucial for identifying novel therapeutic targets and understanding disease progression at the molecular level.
Energy Homeostasis Studies: The dual agonist properties of NN9828 make it an ideal candidate for studies focused on energy balance and expenditure. By engaging both glucagon and GLP-1 pathways, the compound can be used to assess changes in food intake, satiety signaling, and thermogenic responses in controlled laboratory settings. Researchers utilize Survodutide to manipulate appetite-regulating circuits and monitor downstream effects on body weight and adiposity. Such studies provide valuable data on the hormonal regulation of energy homeostasis, supporting the development of new strategies for managing metabolic imbalances.
Pharmacological Profiling: Survodutide is frequently employed in pharmacological studies aimed at characterizing receptor binding, signal transduction, and downstream biological effects. Its dual receptor activity enables the detailed analysis of agonist efficacy, potency, and receptor selectivity in vitro and in vivo. Scientists can use the compound to map signaling pathways, identify potential off-target effects, and optimize dosing regimens for future drug development. These investigations contribute to a deeper understanding of peptide-based therapeutics and their applications in metabolic research.
Peptide Engineering and Structure-Activity Relationship (SAR) Analysis: The molecular design of Survodutide provides a model for peptide engineering and SAR studies. Researchers leverage its structure to develop new analogs with improved pharmacokinetic properties or altered receptor specificity. By systematically modifying amino acid sequences and assessing biological activity, scientists gain insights into the structural determinants of receptor binding and functional selectivity. These efforts facilitate the rational design of next-generation incretin mimetics and expand the toolkit available for metabolic research.
Preclinical Model Development: NN9828 is instrumental in establishing and validating preclinical models of metabolic dysfunction. Its dual action allows for the induction of specific metabolic phenotypes, enabling the evaluation of novel interventions or combination therapies. Laboratories utilize Survodutide to test hypotheses related to hormone signaling, nutrient sensing, and metabolic adaptation under various experimental conditions. The resulting data inform the design of translational studies and support the identification of biomarkers for metabolic disease progression.
In summary, Survodutide's robust dual agonist activity and well-characterized molecular profile make it a versatile and indispensable compound for research applications in metabolic disease modeling, energy homeostasis, pharmacological profiling, peptide engineering, and preclinical model development. Its integration into experimental workflows accelerates the discovery of new insights into hormone regulation and metabolic health, driving progress in both academic and industrial research settings.
1. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
3. High fat diet and GLP-1 drugs induce pancreatic injury in mice
5. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More